Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 22 Issue 1, January 2022

Going in cycles, inspired by the Review on p5.

Cover design: Lara Crow.

Volume 22 Issue 1

Research Highlights

  • Advertisement

  • Pernigoni et al. present a unique mode of non-genetic resistance accounting for castration-resistant prostate cancer that is mediated by androgen-synthesizing gut microbiota.

    • Anna Dart
    Research Highlight
  • Klemm et al. examined the role of tumour-associated macrophages (TAMs) at different stages of brain metastasis in mouse models and found that targeting TAMs by inhibiting both CSF1R and STAT5 might have long-lasting efficacy and prevent resistance.

    • Sarah Seton-Rogers
    Research Highlight
  • Guo et al. have developed a novel strategy, which involves coating tumour cells with silica, to enable personalized cancer vaccines to overcome the immunosuppressive effects of the tumour microenvironment.

    • Anna Dart
    In Brief
  • Kaushik Tiwari et al. have developed a strategy to directly target amplified genes in cancer using triplex-forming oligonucleotides, which selectively induce DNA damage and apoptosis in cancer cells with copy number gains.

    • Anna Dart
    In Brief
Top of page ⤴


  • This Review discusses the concept of transcription cycles in cancer, providing a framework for our understanding of dysregulated transcription in cancer and therapeutic targeting of dysregulated transcription cycles.

    • Stephin J. Vervoort
    • Jennifer R. Devlin
    • Ricky W. Johnstone
    Review Article
  • This Review discusses the context-dependent functions of transforming growth factor-β (TGFβ) with regard to the composition and behaviour of different cell populations in the tumour immune microenvironment, as well as emerging data that demonstrate that TGFβ inhibition can restore cancer immunity.

    • Daniele V. F. Tauriello
    • Elena Sancho
    • Eduard Batlle
    Review Article
  • BH3-mimetic drugs have been designed to directly induce apoptosis in cancer cells by targeting prosurvival BCL-2 family proteins. This Review discusses their continued development and the challenges arising from their implementation in the clinic, such as resistance or on-target toxic effects, and the approaches that could be harnessed to overcome these obstacles.

    • Sarah T. Diepstraten
    • Mary Ann Anderson
    • Gemma L. Kelly
    Review Article
Top of page ⤴


Quick links